King Pharmaceuticals KG Ratios & Valuation
| FY'25 | ||
|---|---|---|
| Efficiency | ||
| Asset turnover | 0.1×— | |
| Leverage | ||
| Debt-to-equity | 1.4×+1.3× | |
| Debt-to-assets | 0.2×+0.1× | |
| Per Share | ||
| Book value per share | $22.38+1,236% | |
| Valuation | ||
| Market capitalization | $70.42M-67.6% | |
| Enterprise value | $184.93M-50.0% | |
| Price / sales | 1.6×-24.3× | |
| Price / book | 0.7×-1.0× | |
| EV / sales | 4.5×-41.9× | |
| Dividend yield | 50.5%— |
Questions, answered.
- Where do King Pharmaceuticals's ratios come from?
- Every ratio is computed from King Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
